483
Aquestive Therapeutics Inc.Aquestive Therapeutics Inc. – FDA 483, Oct 7, 2021
Record Details
An FDA inspection of Aquestive Therapeutics Inc. revealed significant deficiencies in their post-marketing adverse drug experience reporting system. The firm lacked complete written procedures for surveillance, receipt, evaluation, and reporting of adverse drug experiences. Additionally, the company failed to submit several required periodic and annual reports in a timely manner for their approved drug applications, indicating systemic issues with pharmacovigilance compliance.
View Company Profile
ID · 8a5c02ec-4264-46b0-a064-c4c2c3bd734a
Other documents for Aquestive Therapeutics Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.